Home>Topics>Stocks>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals REGN

  1. All
  2. Commentary
  3. Headlines
    1. REGN


      Tue, 25 Nov 2014

      Can anyone provide some insight on why they think this company would be a Great Investment? Thank you for the input!

    2. Sifting Through Fidelity's Large-Cap Medalists


      Thu, 3 Apr 2014

      Some of his biggest winners in recent years are shares he bought years ago when they were much smaller, including Regeneron REGN and Salesforce.com CRM. Wymer has beaten large-growth peers during his tenure, albeit with greater volatility. Wymer doesn

    3. From Barron’s, March 31, 2014 (Part 2)


      Sat, 29 Mar 2014

      relative to sectors such as IT that require lesser capex. Some highflyers sank last week, e.g. biotechs [ ALXN, CELG, GILD, REGN ] and other momentum favorites [ GMCR, FB, TWTR, P, YELP, NFLX, BIDU ]; fears of higher rates and weaker economy were

    4. From Barron’s, March 24, 2014 (Part 2)


      Sat, 22 Mar 2014

      Isaly , the manager of Eaton Vance health sciences ETHSX . He still likes biotechs and pharma. His picks are AGN, ESRX, ISRG, REGN , RHHBY ; also mentioned are BIIB, GILD, PCYC, MDVN, ALPMY, ABBV, JAZZ, PRGO, ACT, JNJ, BMY, MRK, A . Pg 30: Electronic

    5. FDA probes cognitive impact of new cholesterol drugs


      Fri, 7 Mar 2014

      (Reuters) - The Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said...

    6. Regeneron forecasts strong Eylea sales; shares rise


      Tue, 11 Feb 2014

      (Reuters) - Regeneron Pharmaceuticals Inc forecast U.S. sales of eye drug Eylea to reach $1.7-$1.8 billion in 2014 as it expects the drug to win approval for newer uses, sending its shares up 3...

    7. T. Rowe Price Thrives Despite a Tumultuous 2013


      Tue, 21 Jan 2014

      Sciences and others across the complex, often with successful results. In fact, health-care picks such as Regeneron Pharmaceuticals REGN have been big contributors to many diversified funds in recent years, meaning the departures were felt well

    8. UPDATE 1-Regeneron's Eylea beats laser in eye-edema study


      Mon, 21 Oct 2013

      Oct 21 (Reuters) - Regeneron Pharmaceuticals Inc said its drug Eylea improved vision in a late-stage trial far better than standard laser treatment among patients with a common form of vision loss...

    9. First Positive Phase III Results for PCSK9 Drug Reinforce Previous Data


      Wed, 16 Oct 2013

      announced positive results in the first trial of their extensive Phase III ODYSSEY program (12 trials in total) for alirocumab ( REGN -727), which targets PCSK9 to lower LDL (or “bad”) cholesterol. Alirocumab showed a 47.2% reduction in LDL levels from

    10. Allergan Defends Its Territory Against Increased Competition


      Mon, 14 Oct 2013

      licensed anti-VEGF DARPin, for example, has the potential to beat out Roche's RHHBY Lucentis and Regeneron/Bayer's REGN /BAYRY Eylea in the wet AMD market. In dermatology, Allergan has brow and scalp hair growth versions of its novel eyelash

    « Prev12345Next »
    Content Partners